Biosciences Company Broken String Raises $15M for Genomics Platform
Broken String Biosciences, headquartered in Cambridge, UK, is a genomics company focused on developing a technology platform for cell and gene therapies. Recently, the company announced that it has raised $15 million in Series A funding. Leading the round were investors Illumina Ventures, Mérieux Equity Partners, and HERAN Partners, with existing investors Tencent and Dieter von Holtzbrinck Ventures also participating. As part of the funding round, Yoann Bonnamour from Mérieux Equity Partners and Arnaud Autret from Illumina Ventures will join the company's Board of Directors. The funds raised will be used to further develop the company's Next Generation Sequencing-based DNA break mapping platform, INDUCE-seq™, and expand its capabilities to go beyond gene editing, driving commercial growth.
The investment will also support Broken String Biosciences' ongoing expansion plans, including the recruitment of new talent for its UK team based at the Wellcome Genome Campus in Cambridge, as well as the establishment of a US office.
The company's CEO, Felix Dobbs, will lead these efforts. The platform provided by Broken String Biosciences, INDUCE-seq, offers researchers the ability to assess the specificity of genome editing tools and evaluate the associated off-target genetic outcomes. By utilizing a novel PCR-free approach to directly measure and quantify DNA double-strand breaks using NGS, the platform overcomes the limitations of existing gene editing off-target measurement methods. This technology provides valuable insights throughout the therapeutic target discovery, pre-clinical, and clinical development stages to advance gene editing programs.
This funding round and the addition of new investors reflect the growing interest and potential of Broken String Biosciences' technology platform. With the support of these investors and the expertise of its newly appointed Board members, the company is well-positioned to further develop its INDUCE-seq platform into a scalable 'Platform as a Service' offering. Additionally, the company aims to broaden its go-to-market strategy and drive commercial traction by expanding its capabilities beyond gene editing. Broken String Biosciences' innovative approach has the potential to revolutionize the field of genomics and contribute to the advancement of cell and gene therapies.
They've invested in Broken String Biosciences
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 MĂ©rieux Equity Partners( ) | ||||
 Tencent( ) | ||||
 Dieter von Holtzbrinck Ventures( ) | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK